Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 Green Flags for Ocugen's Future


Shares of Ocugen (NASDAQ: OCGN) skyrocketed last year as the company planned to enter the lucrative coronavirus vaccine market. Unfortunately, the company's candidate, Covaxin, has yet to earn emergency use authorization (EUA) where it matters for Ocugen's purposes.

As a result, shares of the eye disease-focused biotech have crashed, losing 72% of their value in the past three months. While Ocugen looks risky, there are reasons why it has a chance to bounce back.

Let's discuss two green flags for Ocugen's future and decide whether they make shares of this clinical-stage biotech a buy. 

Continue reading


Source Fool.com

Like: 0
Share

Comments